Most papillary thyroid carcinomas (PTC) have an isozyme-specific reduction of protein kinase C (PKC)e, which occurs through a post-transcriptional mechanism. Here, we test whether the oncoprotein RET/PTC could be responsible for this effect, since RET/PTC rearrangements are quite prevalent in PTC and RET/PTC activates PLCc, an upstream modulator of PKCs. At 3 h after induction of RET/PTC1 or RET/PTC3 expression, there was evidence of PKCe activation. Activation was restricted to PKCe, as acute expression of RET/PTC did not change the subcellular distribution of other PKC isozymes expressed in PCCL3 cells. Prolonged RET/ PTC expression (2-6 days) produced an isozyme-specific change in PKCe subcellular localization and a decrease in total PKCe levels. The expression of RET/PTC3 Y541F , which does not interact with PLCc, but signals normally through other RET effectors, had no effect on PKCe distribution at any of the time points examined. However, downregulation of total PKCe levels was only partially prevented by expression of RET/PTC Y541F . Cells with decreased PKCe following prolonged expression of RET/ PTC were relatively resistant to doxorubicin-induced apoptosis. Based on our previous observation that PCCL3 cells expressing a dominant-negative PKCe are also markedly resistant to apoptosis, we propose that selective downregulation of PKCe following prolonged RET/PTC activation promotes cell survival and clonal expansion.
Introduction
Protein kinase C (PKC) is a family of serine-threonine kinases, initially discovered on the basis of its activation in vitro by Ca 2 þ , phospholipids and diacylglycerol (DAG). This family consists of at least 12 isozymes that differ in their structure, cofactor requirements for activation, subcellular localization, and substrate specificity (reviewed in Dempsey et al., 2000) . PKC isozymes regulate cell growth (Fujimoto and Brenner-Gati, 1992; Cacace et al., 1993; Mischak et al., 1993; Ahmad et al., 1994) , differentiation (Gamard et al., 1994; Wooten et al., 1994) , and apoptosis (Sawai et al., 1997; Knauf et al., 1999) in a variety of cell types. The expression, subcellular localization, and biological properties vary between isozymes as well as between cell types, allowing for considerable functional diversity (reviewed in Hug and Sarre, 1993) . There is interest in the potential role of PKC isozymes in the multistage process of carcinogenesis (O'Brian and Ward, 1989; Blobe et al., 1994) . This stems in part from the observation that activation of PKC by phorbol esters such as phorbol 12-myristate 13-acetate (PMA) promotes tumor formation in mouse keratinocytes (reviewed in DiGiovanni, 1992; Marks and Gschwendt, 1995) . Given the potential of PKC isozymes to regulate signal transduction pathways in ways that can either promote or inhibit transformation, it is likely that alteration in their function may occur during progression of human tumors, including those of the thyroid. We previously reported that somatic mutations in PKCa or PKCe were not present in thyroid neoplasms (Knauf et al., 2002) . However, in eight of 11 papillary carcinomas we did find a significant isozymespecific reduction in PKCe protein levels, which occurred through either translational or post-translational mechanisms (Knauf et al., 2002) . One possible explanation for this observation is that a sustained upstream activation signal may lead to downregulation of the isozyme (Lu et al., 1998) . A candidate upstream regulator of PKCe in papillary carcinomas is the RET/ PTC oncoprotein, which results in constitutive activation of the Ret kinase (reviewed in Vecchio and Santoro, 2000; Santoro et al., 2002) and is believed to play a causative role in a significant proportion of these tumors (Viglietto et al., 1995; Fagin, 2002) . RET/PTC phosphorylates and activates PLCg (Borrello et al., 1995) , an upstream regulator of PKCs (Kim et al., 2000) . Here, we examined the acute effects of RET/PTC on PKC isozyme activation in thyroid PCCL3 cells with inducible expression of the oncoprotein, and report that only PKCe, and no other PKC isozyme, is activated through this pathway.
Results
In a previous report, we demonstrated that in 73% of the papillary thyroid carcinomas (PTCs) examined there was a 50-90% reduction in PKCe protein levels compared to that observed in the corresponding normal thyroid tissue (Knauf et al., 2002) . We hypothesized that the decreased PKCe levels may be the result of chronic activation and subsequent downregulation of the isozyme. To explore whether activation of RET/PTC could be responsible for this effect, we used the previously described cell lines RET/PTC3 and RET/ PTC1 (Wang et al., 2003) with doxycycline-inducible expression of RET/PTC1 or RET/PTC3, respectively. We have shown that in PCCL3 cells, PKCe activation is detected by reduced levels in the soluble (inactive) fraction (Knauf et al., 1999) . Western blots from cells harvested 3 or 6 h after induction of RET/PTC1 or RET/PTC3 had decreased PKCe in the soluble fraction, consistent with activation of PKCe ( Figure 1a ). PKC activation was restricted to PKCe as the abundance of the other PKC isozymes (a, bI, and z) expressed in PCCL3 cells did not change (Figure 1 ). However, treatment with 100-nm PMA, a known activator of classical and novel, but not atypical PKC isozymes, decreased PKCa and PKCbI in the soluble extracts ( Figure 1 ) with a corresponding increase in the particulate fraction (not shown). Particulate levels of PKCe are not significantly increased with acute expression of RET/PTC (not shown) and are only marginally increased with PMA ( Figure 2 ). As expected, levels of Figure 1 Effects of acute expression of RET/PTC on PKCe subcellular distribution. Cells were incubated with H3 medium for 3 days prior to the addition of doxycycline for 3 or 6 h. (a) Protein (50 mg) from the soluble fractions isolated from the indicated cell lines treated with doxycycline was subjected to SDS-PAGE and transferred onto a nitrocellulose membrane. PKCe, PKCbI, PKCz, and PKCa were detected by Western blotting with rabbit polyclonal anti-PKCe, anti-PKCbI, anti-PKCz, or anti-PKCa IgG, respectively (Santa Cruz, CA, USA), and HRP-conjugated goat anti-rabbit IgG. As a control for PKC activation, cells were treated with 100-nm PMA for 20 min. (b-d) Bars represent the average percent change in PKC soluble levels compared to untreated RET/PTC1 cells (b), RET/PTC3 cells (c), or rtTA cells (d) from six, four, and three independent experiments, respectively. After doxycycline-induced RET/PTC expression in RET/PTC1 and RET/PTC3 cells, but not in the rtTA control cell line, there was a significant decrease in PKCe in the soluble fraction, *Po0.05 and **Po0.001 using ANOVA with post hoc analysis. Doxycycline treatment of the control cell line rtTA was without effect. The other PKC isozymes expressed (a, bI, and z) in the PCCL3 cells were not significantly affected. (e) PKCe was immunoprecipitated from the total cell extract prepared from RET/PTC3 cells incubated with 100-nm PMA for 20 min or 1.0 mg/ml of doxycycline for 4 h using a mouse anti-PKCe IgG. The resulting immunoprecipitate was then incubated with ATP g 32 P using myelin basic protein as a substrate as described in Materials and methods. Phosphorylation of myelin basic protein was not observed when normal mouse IgG was used for immunoprecipitation. The kinase reactions were then subjected to SDS/PAGE and phosphorylation of myelin basic protein was detected using phosphoimager. Bars represent the average PKCe kinase activity from two experiments performed in duplicate. *Po0.006 versus -doxycycline using a Student's t-test PKCz did not change with PMA. Quantitation of changes in PKC soluble levels from at least four separate experiments demonstrated a 40-50% decrease in PKCe in the soluble fraction 3 and 6 h after induction of RET/PTC1 or RET/PTC3. However, no significant change was detected in levels PKCa, bI, or z (Figure 1b-d) . To confirm increased PKCe activity with acute RET/ PTC expression, PKCe was immunoprecipitated and the immunoprecipitate used in in vitro kinase assays. PKCe activity was increased by sixfold in cells treated with PMA and by threefold in RET/PTC3 cells treated with doxycycline for 4 h (Figure 1e) .
To determine the effects of sustained RET/PTC expression on PKCe activity, we performed Western blots of soluble and particulate fractions from cells harvested 48 or 96 h after induction of RET/PTC1 or RET/PTC3 (Figure 2a ). RET/PTC3 or RET/PTC1 expression for 96 h induced a 2.1-and 2.8-fold increase in PKCe abundance in soluble extracts, compared to that observed in the untreated cells, respectively (Figure 2b ). Furthermore, a 30-50% reduction in PKCe protein was found in the respective particulate fraction (Figure 2b ). After normalization for PKCe mass, PKCe activity was increased by B20% in cells chronically expressing RET/PTC3 compared to control cells (data not shown).
To determine the effects of chronic RET/PTC expression on PKCe levels Western blots containing total cell extracts were probed with an anti-PKCe IgG. Chronic doxycycline-induced activation of RET/PTC1 or RET/PTC3 evoked a time-dependent decrease in total PKCe levels, reaching 50% of control 6 days after RET/PTC expression ( Figure 3 ). As with changes in PKC subcellular distribution, the decrease in total PKCe levels observed after chronic expression of RET/PTC was isozyme specific, as PKCa (Figure 3) , PKCbI, and PKCz were not significantly affected (data not shown). Real-time RT-PCR analysis of PKCe expression in cells expressing RET/PTC3 for 2-6 days demonstrated no significant change in PKCe mRNA levels (data not shown), indicating that the RET/PTC-induced decrease in PKCe protein levels was due to post-transcriptional changes.
The increase in soluble fraction and decrease in particulate and total levels of PKCe observed with chronic RET/PTC is consistent with downregulation of PKCe activity. Given our previous observation that a dominant-negative inhibitor of PKCe blocked doxorubicin-induced apoptosis in PCCL3 cells (Knauf et al., 1999) , it is possible that the RET/PTC-induced downregulation of PKCe may result in relative resistance to apoptosis. To explore this, the RET/PTC3 cell line was incubated with doxycycline for 5 days and then treated with doxorubicin, a DNA-damaging agent, for the indicated times. In cells not expressing RET/PTC (i.e. no doxycycline), only 27% survived exposure to doxorubicin (Figure 4a ). By contrast, chronic expression of RET/PTC increased survival by twofold (Figure 4a ), which was confirmed, using an APO-BrdU assay, to be due to a decrease in apoptosis (Figure 4c ). However, when cells were treated with doxycycline for only 12 h prior to the addition of doxorubicin, the expression of RET/PTC3 had no significant effect on doxorubicininduced apoptosis (Figure 4b ).
RET/PTC3 binds to PLCg through phosphotyrosine 541, which in turn promotes phosphorylation of PLCg at Tyr783, increasing the hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP 2 ) to inositol 1,4,5-triphosphate (IP 3 ) and DAG. To investigate whether the activation of PLCg by RET/PTC was responsible for the changes in PKCe that we described, we created a cell line with doxycycline-inducible expression of RET/ PTC3
Y541F
. To confirm that this amino acid change blocked RET/PTC-induced activation of PLCg in PCCL3 cells, the RET/PTC3 and RET/PTC3 Y541F cells were treated for 12 or 24 h with doxycycline and total cell extracts were prepared. PLCg was then immunoprecipitated from the cell extracts and the resulting immunoprecipitate was subjected to Western blotting with anti-phosphotyrosine or anti-PLCg. As shown in Figure 5a , expression of RET/PTC3, but not RET/ PTC3 Y541F , increased PLCg phosphorylation. The RET/ PTC3-induced increase in phospho-PLCg was confirmed to be at least in part due to phosphorylation of PLCg at tyrosine 783 by probing Western blots containing total extracts from cells expressing RET/PTC3 with antiphospho-PLCg (Tyr783) (Figure 5b ). By contrast, cells expressing RET/PTC3 Y541F did not exhibit an increase in phosphorylation of PLCg at Tyr783 (Figure 5b ).
To investigate whether PLCg phosphorylation mediates effects of acute RET/PTC expression on PKCe, Western blots containing the soluble fractions from RET/PTC3 Y541F cells harvested 3 or 6 h after induction of RET/PTC3 Y541F were probed with an anti-PKCe IgG. As shown in Figure 6a , acute expression of RET/PTC3 Y541F had no significant effect on PKCe levels in the soluble fraction, indicating that activation of PLCg was required for the cellular redistribution of PKCe after acute expression of the oncoprotein. Moreover, the Y541F mutant was also unable to produce the redistribution of PKCe observed with chronic RET/PTC3 expression ( Figure 6b ). However, the Y541F mutation only partially prevented the decrease in total PKCe levels observed with chronic RET/PTC expression (Figure 6c ), indicating the involvement of other pathways activated by RET/PTC in the decrease of total PKCe levels. Next, we examined the role of PLCg in the increased resistance of PCCL3 cells to doxorubicin-induced apoptosis after chronic expression of RET/PTC3 by incubating RET/PTC3 Y541F cells with doxycycline for 5 days prior to the addition of doxorubicin for 24 h. In contrast to RET/PTC3, chronic expression of RET/ 
PTC3
Y541F did not protect PCCL3 cells from doxorubicin-induced apoptosis (Figure 6d and e) . This result is consistent with a role of PLCg/PKCe in the increased resistance to doxorubicin-induced cell death after chronic expression of RET/PTC3.
Discussion
PTCs commonly have isozyme-specific reduction in PKCe due to a post-translational effect (Knauf et al., 2002) . We hypothesized that this may be due to downregulation of the isozyme as a result of sustained activation, thus triggering degradation via the ubiquitin- Y541F cells were incubated with H3 medium for 3 days prior to the addition of doxycycline for 3-6 h. Protein (50 mg) from soluble fractions was subjected to SDS-PAGE, transferred onto a nitrocellulose membrane, and Western blotted with either anti-PKCe or anti-RET IgG. Bars in the graph to the right represent the average percent change in PKCe soluble levels compared to untreated cells from six experiments. As a control for PKCe activation, cells were treated for 20 min with 100-nm PMA. (b) RET/PTC3 Y541F cells were incubated with H4 medium with or without doxycycline for 48-96 h. Protein (50 mg) from soluble and particulate fractions was subjected to SDS-PAGE, transferred onto a nitrocellulose membrane, and Western blotted with an antiPKCe IgG. Bars in the graph to the right represent the average percent change in PKCe levels compared to untreated cells from five independent experiments. (c) RET/PTC3 Y541F cells were incubated in H4 medium containing doxycycline for 2-6 days. Protein (50 mg) from total cell extract was subjected to SDS-PAGE, transferred onto a nitrocellulose membrane, and Western blotted with either an anti-PKCe or anti-RET IgG. Bars in the graph to the right represent the average percent change in total PKCe levels from untreated cells from eight experiments. (d) RET/ PTC3 Y541F cells were treated with 1.5 mm doxorubicin at 371C for 24 h. Bars represent the percent of cells surviving doxorubicin exposure versus those in the absence of doxorubicin, as determined by MTT assay. Data represent the mean of single experiment performed in triplicate. Similar results were obtained in four independent experiments. *Po.05 and **Po0.001 using ANOVA with post hoc analysis. ***Po0.003 using a two-tailed ttest. (e) RET/PTC3 Y541F cells were treated with 1.0 mg/ml doxycycline for 5 days prior to the addition of 1.5 mm doxorubicin for 40 h. Apoptosis was measured by ApoBrdU assay (PharMingen, San Diego, CA, USA). Bars represent the average percent of BRDU-positive cells (ApoBrdU) from a single experiment performed in triplicate. Similar results were obtained in an additional independent experiment. ***Po0.0003 using a twotailed Student's t-test proteasome pathway (Lu et al., 1998) . In this report we examined whether the oncogene, RET/PTC, which is commonly expressed in PTCs, could lead to constitutive activation and subsequent downregulation of PKCe. We show that acute expression of RET/PTC selectively activates PKCe, based on evidence that PKCe redistributes away from the soluble fraction and that PKCe kinase activity is increased. We did not observe a corresponding increase of PKCe in the particulate fraction. We believe this is due to the fact that most of the cellular content of PKCe is contained in this heterogeneous particulate fraction even in the inactive state, making the relative increase after activation very hard to detect reliably (i.e. there is only a 15% increase after treatment with PMA despite a sixfold stimulation of PKCe kinase activity).
By contrast, prolonged RET/PTC decreases total and particulate PKCe, which is consistent with classical PKC downregulation. However, the increase in soluble PKCe levels does not fit this paradigm. It is possible that the latter is due to a block in translocation. This could theoretically be due to interference with binding of PKCe to its receptor for activated C kinase (RACK) following activation, or to increased affinity to receptor for inactivated C kinase (RICKs) in the cytosol that retains it in an inactive conformation (Mochly-Rosen and Gordon, 1998; Schechtman and Mochly-Rosen, 2001). Anchoring of PKCe to its RACK is required for phosphorylation of its substrate (Mochly-Rosen and Gordon, 1998; Schechtman and Mochly-Rosen, 2001) and helps protect the activated PKCe from degradation (Mochly-Rosen, personal communication). After normalization to PKCe mass, PKCe kinase activity is slightly increased in cells with chronic expression of RET/PTC, which is consistent with a reduced ability of the activated kinase to bind its anchoring protein. Thus, a combination of factors appears to be at play. Lower total PKCe levels indicate downregulation and, as stated, there may also be some interference with translocation, the mechanism of which is unknown, except that this effect requires activation of PLCg, since it is not seen after activation of RET/PTC Y451F . Regardless of these distinctions, both downregulation and translocation interference ultimately would result in a decrease in phosphorylation of downstream target/s of PKCe.
The effects of RET/PTC expression are specific to PKCe as distribution and expression of the other PKC isozymes was not affected. Although the novel and classical PKC isozymes are activated by similar upstream signals (i.e. DAG), selective activation of a single PKC isozyme has been reported (reviewed in Ron and Kazanietz, 1999) . For example, selective activation of the PKCe isozyme is observed after exposure of NIH 3T3 (Zhuang et al., 1997) and SKBR-3 (Ohmori and Arteaga, 1998) cells to UV and cis-diamminedichloroplatinum(II) (CDDP), respectively.
How selective activation of PKC isozymes is accomplished is not well understood. One potential mechanism is differential lipid requirements. For example, free fatty acids can synergize with DAG for PKC activation (Shinomura et al., 1991) . Similarly, the short-chain phosphatidylcholine derivatives lysophosphatidic acid and phosphatidylinositol 3,4,5-triphosphate can activate PKC isozymes, perhaps with some degree of selectivity. One exciting finding supporting this concept is that the acidic phospholipid phosphatidylglycerol stimulates PKCbII in nuclear membranes, leading to phosphorylation of nuclear substrates by these isozymes. Identification of a phosphatidylglycerol-binding site at the carboxyl-terminal region of PKCbII provides the first evidence of a phospholipid-binding site in the catalytic domain, and points to a high degree of complexity in the regulation of PKC activity by lipids (Murray and Fields, 1998) . The signal transduction pathway utilized to stimulate DAG production may also be a factor in determining which PKC isozymes are activated. For example, in the human promyelocytic leukemia cell line HL-60 treatment with insulin-like growth factor-I, which increases nuclear levels of DAG through activation of PLD1/2, stimulates proliferation and migration of PKCbII towards the nucleus (Neri et al., 2002) . By contrast, treatment with dimethyl sulfoxide, which increases nuclear DAG levels via a PLD1/2-independent pathway, stimulates differentiation and migration of PKCa towards the nucleus (Neri et al., 2002) .
RET/PTC activates a number of signal pathways through interactions of intermediates with phosphorylated tyrosine residues in the kinase domain. RET/PTC binding to and activation of PLCg has been demonstrated (Durick et al., 1996) . Indeed, we show in Figure 5a that expression of RET/PTC produces a large and sustained increase in the activation of PLCg. To investigate the role of PLCg in RET/PTC-induced activation and subsequent effects on PKCe, we expressed RET/PTC3 Y541F , an RET/PTC3 mutant that was unable to activate PLCg, but able to activate other signaling pathways downstream of RET/PTC. RET/ PTC3 Y541F was unable to duplicate the effects of acute or prolonged RET/PTC expression on PKCe activation or expression, demonstrating a role for Y541 and in all probability PLCg in the effects of RET/PTC on PKCe activation and expression.
The changes in PKCe distribution and expression observed with prolonged expression of RET/PTC are consistent with reduced signaling through PKCe. This in turn would be predicted to increase the survival of thyrocytes, as we previously demonstrated that inhibiting PKCe through expression of a competitive antagonist protects thyroid cells from DNA damage-induced apoptosis (Knauf et al., 1999) . Accordingly prolonged expression of RET/PTC, which inhibits signaling through PKCe, is associated with increased resistance to doxorubicin-induced apoptosis. By contrast, acute expression of RET/PTC3 or prolonged expression of RET/PTC3 Y541F , conditions that do not downregulate PKCe do not increase the resistance of PCCL3 cells to cell death induced by DNA damage. The lack of protection of PCCL3 cells to doxorubicin-induced apoptosis with the expression of RET/PTC3 Y541F implicates signaling via PLCg in the antiapoptotic effects of RET/PTC. Interestingly, other groups have demon-strated that activation of PLCg is responsible for the antiapoptotic effect of the oncogene Kit (Plo et al., 2001; Maddens et al., 2002) , which like RET, is a tyrosine kinase receptor. RET/PTC expression alone promotes a slight increase in apoptosis (Castellone et al., 2003; Wang et al., 2003) . However, here we show that after prolonged RET/PTC activation, cells become resistant to apoptosis induced by a DNA-damaging agent. We do not precisely understand these contrasting effects, but notably a number of other oncoproteins (i.e. Ras) also exhibit both proapoptotic and antiapoptic properties depending on the stimulus and culture conditions (Downward, 1998) .
These results support a model of tumor initiation by RET/PTC in which selective downregulation of PKCe promotes clonal expansion by promoting survival of the transformed cell.
Materials and methods

Cell culture
The well-differentiated rat thyroid cell line PCCL3 (Fusco et al., 1987) was propagated in an H4 medium, which consisted of Coons modification of Ham's F12 media (Irvine Scientific, Irvine, CA, USA) containing 5% fetal calf serum, glutamine (286 mg/ml), apo-transferrin (5.0 mg/ml), hydrocortisone (1.0 nm), insulin (1.0 mg/ml), TSH (1.0 mIU/ml), penicillin and streptomycin. H3 medium is identical to H4 medium, except TSH has been omitted.
DNA constructs and site-directed mutagenesis
The RET/PTC3 and RET/PTC1 cDNAs (a generous gift from Sissy Jhiang, Ohio State University) were cut with XbaI and SacII and the resulting DNA fragments ligated into pUG10-3 previously restricted with XbaI and SacII. The RET/PTC3 Y541F construct was created by changing tyrosine 541 of RET/PTC3 (corresponding to tyrosine 1015 in full-length RET) to phenylalanine using a previously described method). Briefly, fragment A was created with the pUHG10-3 vector-specific sense primer ret-F1 5 0 agctcgtttagtgaa3 0 , the RET/PTC3 specific anti-sense primer ret-R2 5 0 tagtctcagggccgtcgtcataaa3 0 , using the pUHG 10-3-RET/PTC3 cDNA as a template. The underlined region of primer ret-R2 corresponds to the RET/ PTC3 cDNA. Fragment B was created by amplification of the same template with RET/PTC3-specific sense primer ret-F2 5 0 aggagagactTcttggacctt3 0 and the vector-specific anti-sense primer ret-R1 5 0 ttctaaacaacaccctg3 0 . The sense primer converted the codon corresponding to amino acid 1015 in fulllength Ret from TAC to TTC. Fragments A and B were then denatured, annealed and amplified using the primers ret-F1 and ret-R1. The resulting PCR product was then cut with XbaI and SacII, and ligated into the pUG10-3 vector. The correct cDNA sequence was then verified using an ABI sequencing machine.
Cell lines
The rtTA-7 cell line was created by stably transfecting PCCL3 cells Shirokawa et al., 2000) with pUHD172-1neo, which directs high-level expression of the reverse tetracycline transactivator protein (Gossen et al., 1995) . PCCL3 cell lines with doxycycline-inducible expression of RET/PTC3 or RET/PTC3
Y541F were created by subcloning the respective cDNA into the pUHG 10-3 vector (Gossen and Bujard, 1992) , downstream of the heptamerized tetO and a minimal CMV promoter (Gossen and Bujard, 1993) . The constructs were then cotransfected with TKhygro, which contains the hygromycin gene under control of a minimal TK promoter, into the rtTA-7 cell line. As a control pUHG 10-3 vector was transfected into the PCCL3-rtTA-7 cell line to generate rtTA-Cl3.
Total cell lysates
Cells were harvested and placed in ice-cold buffer A (10 mm Tris-HCl pH 7.5, 5 mm EDTA, 100 mg/ml PMSF, 4 mm EGTA, 1 mg/ml aprotinin, 5 mg/ml E-64, 1 mg/ml leupeptin, and 1 mg/ml pepstatin) containing 1% Triton X-100 and lysed by passage through a 27-gauge needle. The lysate was then centrifuged at 10 000 g for 15 min at 41C, the supernatant was collected and the protein concentration was determined. An equal amount of protein from each sample was then subjected to SDS-PAGE.
Preparation of soluble and particulate fractions
Cells were harvested and placed in ice-cold buffer A and then lysed by passage through a 27-gauge needle. Soluble and particulate fractions of the cell lysates were then separated by centrifugation at 100 000 g for 1 h at 41C. The supernatant (soluble fraction) was removed and the pellet was resuspended in buffer A containing 1% Triton X-100. The Triton X-100 insoluble material was removed by centrifugation at 100 000 g for 1 h at 41C and the supernatant was collected (particulate fraction). The distribution of the PKC isozymes in the various fractions was then analysed by Western blotting.
Immunoprecipitation
Cells were grown in an H4 medium until confluent and then deprived of TSH (H3 medium) for 2 days. The medium was then replaced with a fresh H3 medium with or without doxycycline (1 mg/ml) and incubated for 12 or 24 h. Cells were lysed in 1 ml of buffer B (50 mm Tris (pH7.5), 200 mm NaCl, 0.5% Nonidet P-40, and 0.5% deoxycholate) and cell lysates were incubated with rabbit anti-PLCg for 1 h at room temperature, followed by a 1 h incubation with protein A/G plus agarose. The agarose beads were then washed three times with buffer B and collected by centrifugation. The immunoprecipitated proteins were then analysed by Western blotting.
Western blot analysis
Protein from the indicated sources were subjected to SDS-PAGE and Western blotted as previously described (Knauf et al., 1999) . Briefly, blots were hybridized with antibodies to the indicated proteins and then with their corresponding species-specific horseradish peroxidase-conjugated secondary IgG and visualized using ECL (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA) as directed by the manufacturer. The images were captured using the Kodak Image Station (Kodak, Eastman Kodak Co., New Haven, CT, USA). To confirm similar loading, the membranes were stained with Ponceau S prior to hybridization with antibodies. The following IgGs were obtained from Santa Cruz (Santa Cruz, CA, USA): rabbit anti-PKCe, rabbit anti-PKCa, rabbit antiPKCbI, rabbit anti-PKCz, rabbit anti-PLCg, and mouse antiphosphotyrosine. Rabbit anti-phospho PLCg was purchased from Cell Signaling (Beverly, MA, USA). Mouse monoclonal anti-RET was a gift from Dr Yuri Nikiforov (University of Cincinnati).
PKCe in vitro kinase assay RET/PTC3 cells were incubated with or without doxycycline for 4 h or with 100 nm PMA for 20 min. Cells were then lysed with buffer K (20 mm Tris-HCl (pH 7.5), 2 mm EDTA, 10 mm EGTA, 0.25 m sucrose, 12 mm b-mercapthoethanol, 17 mg/ml PMSF, 20 mg/ml soybean trypsin inhibitor, 25 mg/ml leupeptin, 25 mg/ml aprotinin, and 0.1% Triton X-100) and PKCe immunoprecipitated from cell lysates with mouse anti-PKCe IgG (gift from Daria Mochly-Rosen, Stanford University). The immunoprecipitate was washed once with buffer A1 (50 mm Tris-HCl (pH7.5), 0.15 m NaCl, 1 mm EDTA, 0.1% Triton X-100), once with buffer A2 (50 mm Tris-HCl (pH7.5), 0.15 m NaCl, 0.1% Triton X-100), once with buffer A3 (50 mm Tris-HCl (pH7.5), 0.1% Triton X-100), and once with 20 mm Tris-HCl (pH7.5). The immunoprecipitate was then resuspended in kinase reaction buffer (20 mm Tris-HCl (pH7.5), 0.33 mCi g 32 P ATP, 100 mm ATP, 0.6 mg/ml myelin basic protein (MBP), and 0.5 Â phospholipids cocktail (Cat.# 20133, Upstate Biotechnology, Waltham, MA, USA)), incubated at room temperature for 15 min and the reaction was stopped by the addition of 30 ml of SDS-PAGE loading buffer. Samples were then subjected to SDS-PAGE, transferred on to nitrocellulose, and phosphorylation of MBP was determined using phosphoimager (Amersham Biosciences, Sunnyvale, CA, USA). Phosphorylation of MBP was then normalized for efficiency of PKCe immunoprecipitation, which was determined by Western blotting of membranes with rabbit antiPKCe as described above.
RNA preparation and real-time RT-PCR analysis
Cells were harvested at the indicated time and was RNA isolated using TRI reagent as directed by the manufacturer (Molecular Research Center, Inc., Cincinnati, OH, USA). Total RNA (2 mg) was reverse transcribed with 200 U of Superscript reverse transcriptase (Gibco-BRL, Grand Island, NY, USA) in the presence of 2.5 mm of random 9-mer primers, 20 mm dNTP for 60 min at 371C, followed by a 5-min heat inactivation at 951C. A volume of 2 ml of the cDNA reaction mixture were then used as a template in a PCR reaction containing 1 mm of the primer pairs for amplification of either b-actin (5 0 ctgaaccctaaggccaaccgtg 3 0 and 5 0 ggcatacaggga cagcacagcc3 0 ) or PKCe (5 0 cgcggaaacacccttatcta3 0 and 5 0 tcac tccatgttggtggaga3 0 ). PCR amplifications were performed using the Fast-Startt DNA Master SYBR Green real-time PCR kit as directed by the manufacturer (Roche Molecular Biochemicals, Indianapolis, IN, USA). The amplification conditions were optimized for the LightCycler instrument (Cepheid, Sunnyvale, CA, USA) and demonstrated to result in a single PCR product by melting curve and electrophoretic analysis. To avoid potential problems from contaminating genomic DNA, PCR primers were designed to span a large intron whose location was determined by blasting the rat PKCe or bactin sequence against the NCBI rat genome database. This was further verified by the lack of a signal when reactions were performed in the absence of reverse transcriptase. The CT value, which was determined using the second derivative, was used to calculate the normalized expression of the PKCe mRNA using the Q-Gene program (Muller et al., 2002) .
MTT assay
To determine cell viability, an MTT assay was performed as previously described (Knauf et al., 1999) . Briefly, the H4 medium was removed from cells and replaced with H4 an medium containing 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St Louis, MO, USA) and incubated for 2 h at 371C. The medium was then removed, and the colored precipitate that was formed by cleavage of MTT in living cells was solubilized with isopropanol containing 0.05 m HCl and absorbance at 570 and 660 nm was determined. The percent cell survival was calculated using the following formula:
APO-BrdU assay APO-BrdU assays were performed following the manufacturer's recommended procedure (PharMingen, San Diego, CA, USA). Briefly, cells were incubated with 1% paraformaldehyde, fixed in 70% ethanol and then stored at À201C until assay. For the DNA-labeling procedure, cells were washed and resuspended in a DNA-labeling solution containing terminal deoxynucleotide transferase (TdT) and Br-dUTP and incubated at 371C for 60 min. After labeling, cells were washed and stained with fluorescein-labeled anti-BrdU antibody for 30 min, and then treated with propidium iodide and RNAse A. APO-BrdU positive cells were evaluated by FACS analysis.
